Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series
Journal of Medical Cases · 2022-05 · 13 (5) · 240-243
DOI: 10.14740/jmc3918 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Medical Cases, 2022-05. Verfasst von Li Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA.
Zitieren
APA
Zhao, L., Singh, V., Ricca, A., & Lee, P. (2022). Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series. Journal of Medical Cases, 13(5), 240-243. https://doi.org/10.14740/jmc3918
Vancouver
Zhao L, Singh V, Ricca A, Lee P. Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series. Journal of Medical Cases. 2022;13(5):240-243. doi:10.14740/jmc3918
BibTeX
@article{Zhao2022,
author = {Zhao, Li and Singh, Vinit and Ricca, Anthony and Lee, Patrick},
title = {Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series},
journal = {Journal of Medical Cases},
year = {2022},
volume = {13},
number = {5},
pages = {240--243},
doi = {10.14740/jmc3918}
}
EUVIMED